You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,892,563

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,892,563

Title:	Methods for treatment of severe acute respiratory syndrome (SARS)
Abstract:	Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
Inventor(s):	Siber; George R. (Irvington, NY)
Assignee:	Wyeth Holdings Corporation (Madison, NJ)
Application Number:	10/441,059
Patent Claims:	1. A method for treating a patient having Severe Acute Respiratory Syndrome (SARS) comprising: administering to the patient a therapeutically effective amount of a medicament comprising an inhibitor of TNF and a pharmaceutically acceptable carrier thereof, wherein the medicament is effective against Severe Acute Respiratory Syndrome (SARS). 2. A method for treating a patient having SARS-associated Coronavirus (SARS-CoV) comprising: administering to the patient a therapeutically effective amount of a medicament comprising an inhibitor of TNF and a pharmaceutically acceptable carrier thereof, wherein the medicament is effective against SARS-associated Coronavirus (SARS-CoV). 3. A method for treating a patient having Severe Acute Respiratory Syndrome (SARS) comprising: administering to the patent a therapeutically effective amount of an inhibitor of TNF. 4. The method of claim 3, wherein the inhibitor of TNF comprises a soluble recombinant receptor, an antibody, a small molecule that affects the activity of TNF, an antisense oligonucleotide or combinations thereof. 5. The method of claim 3, wherein the inhibitor of TNF inhibits TNF-.alpha.. 6. The method, of claim 3, wherein the inhibitor of TNF is etanercept. 7. The method of claim 3, wherein the inhibitor of TNF is an antibody to TNF-.alpha.. 8. The method of claim 3, wherein the inhibitor of TNF is a soluble recombinant receptor. 9. The method of claim 8, wherein the inhibitor of TNF is the p75 TNF receptor.

Details for Patent 7,892,563

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	03/05/2020	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.